I know they got rid of the money s*ck in Finland, but the company doesn't grow, it hasn't made a profit in about ten years, and it doesn't have the R & D resources to keep up with technological innovation. There is only a 20% gross margin in this business.
The market cap is quite a bit over book value, so I don't see what Zacks sees in Planar. In particular, why is this company better than it was one year ago?
Earned eight grand by purchasing shares in the 8-9 dollar range, then patiently holding on for fair value. Even collected two dividend payments.
At one point the annual dividend rate was 5%, go figure. IMO, the price is now more reasonable, so I'm off to a new message board where the other members don't copy everything I post!
An 8 P/E is low for any company, especially one that is expected to grow as fast as ESTE.
Yet the share price has been stuck at a low level for quite a while. Who knows what it will take, or when to get a reasonable valuation based on fundamentals. It's unlikely to happen when all we see are 20 share trading increments like today.
Boolean, Mr Market just hasn't appreciated Earthstone stock, despite the fact the Year to Date earnings are up 152% and Year to Date revenues are up 60%.
I consider this a slight positive surprise. While it doesn't make this stock ready for the moon, it guarantees they have adequate cash flow for the indefinite future.
Sounds like old news that the business with Comcast was in trouble. This just makes it official.
Since PCRX closed at exactly your target price, I'd say you made a pretty good prediction.
Now that we have an update from PCRX on their sales, do you have another prediction for us?
Those attorneys have played dirty for years and gotten away with it. It's about time a company has the guts to counter sue.
I hope the court is as harsh on the attorneys for their alleged fraud, as they have been against the companies that have been only loosely connected to asbestos.
According to the PCRX 10K report, there are 40 million annual opportunities in the US to use EXPAREL. And the average price per vile is $285. Doing the math for a quarter, PCRX just announced $30.5 million in EXPAREL sales which comes out to slightly more than a 1% market share.
I have know idea how good this product is. Can it get a 5% market share? 10%? 50%? And what about worldwide sales?
However the growth over the last year is phenomenal. Hopefully the sales are coming from actual uses as opposed to channel stuffing.
It was create as a spin off from Goodrich, which after acquiring Coltec, spun off all the bad boy subsidiaries that had legacy liabilities.
I have no idea who would give you a thumbs down for that comment other than a troll.
The investment for the Statoil project will end in 12-18 months, so it‘s nice to get a heads up on the next expansion.
Truth, you nailed the boe in your preliminary right to the last barrel. The gas figure is quite notable, up 34.5% from last month, even though last month was the previous best.
However there were only 45 wells listed, same as October and only one above September.
Barring health problems, I don't believe there is any chance Ray would sell now.
Revenues for FYE March 31 2014 are on track for about $17 million. And that revenue figure should double by FYE 2016. It's anyone's guess when the stock might reflect that potential.
Yes, here you are stalking me from the message board of one stock, to another, all at one o'clock in the morning. Are you a night owl?
It would be nice if the payday were this Q, but there are so many factors to consider. I've observed evidence of share price manipulation for more than a year. And it's been on the downside.
In a thinly traded stock like Earthstone there are often large time blocks with no real buyers or sellers other than the designated market makers. That's when some one comes in and walks the share price down on low volume.
Who knows when this will stop.
Earstone should trade at 12-15 times next year's estimated eps. Maybe it's time for Ray to get some advice on achieving shareholder value. Unfortunately, Ray rejected a former board member's advice to engage a PR firm.